PXVX0047 Vaccine + Teva Ad4/Ad7 Vaccine
Phase 1Terminated 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Adenoviral Infection
Conditions
Adenoviral Infection
Trial Timeline
May 1, 2017 → Nov 27, 2017
NCT ID
NCT03160339About PXVX0047 Vaccine + Teva Ad4/Ad7 Vaccine
PXVX0047 Vaccine + Teva Ad4/Ad7 Vaccine is a phase 1 stage product being developed by Emergent BioSolutions for Adenoviral Infection. The current trial status is terminated. This product is registered under clinical trial identifier NCT03160339. Target conditions include Adenoviral Infection.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03160339 | Phase 1 | Terminated |